Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $1.1 billion for Q1 2026.

• Quarterly Other Accumulated Expenses rose 15.25% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 15.25% YoY) and the FY2025 annual result came in at $1.2 billion, up 15.88% from the prior year.
• Other Accumulated Expenses fell to $1.1 billion in Q1 2026, from $1.2 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.2 billion in Q3 2024 and troughed at $900.0 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses climbed 22.75% — and 2025, when it dropped 21.07%.
• Tracing TEVA's Other Accumulated Expenses over 5 years: stood at $1.0 billion in 2022, then grew by 3.88% to $1.0 billion in 2023, then dropped by 2.3% to $1.0 billion in 2024, then gained by 15.88% to $1.2 billion in 2025, then decreased by 6.01% to $1.1 billion in 2026.
• Business Quant data shows TEVA's Other Accumulated Expenses at $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.